Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma

泊马度胺 来那度胺 医学 多发性骨髓瘤 内科学 肿瘤科 队列 耐火材料(行星科学) 进行性疾病 沙利度胺 外科 疾病 天体生物学 物理
作者
Tomer M. Mark,Angelica Falkenstein,Jonathan Kish
出处
期刊:Future Oncology [Future Medicine]
卷期号:18 (5): 553-564 被引量:5
标识
DOI:10.2217/fon-2021-1176
摘要

Aim: To demonstrate the efficacy of pomalidomide for relapsed/refractory multiple myeloma (RRMM) following treatment in real-world, community practice using retrospective database analysis. Materials & methods: US-based community oncologists identified patients with RRMM treated with or without pomalidomide following first-line lenalidomide. Disease response (≥ very good partial response) and progression-free survival were compared. Results: Disease response was 78.6 and 51.7% for pomalidomide (n = 126) and nonpomalidomide cohorts (n = 174), respectively (p < 0.0001). Multivariate adjusted odds of response were 4.5-times greater for pomalidomide cohort (p < 0.0001). Median progression-free survival was not reached for pomalidomide cohort and 16.7 months for nonpomalidomide cohort (log-rank p < 0.01). Conclusion: Following lenalidomide induction in RRMM, pomalidomide is an effective treatment.Plain language summary Treatment options have expanded in recent years for patients with relapsed/refractory multiple myeloma (RRMM) who received lenalidomide as their initial treatment and then either had a period of improvement before the disease worsened or did not respond to the medication at all. Pomalidomide is another MM treatment from the same drug class as lenalidomide. We analyzed the effect of a combination treatment containing pomalidomide versus a combination treatment without pomalidomide in patients with MM who had received routine initial treatment with lenalidomide. US-based community oncologists completed study forms to record patient characteristics and treatment response information. Results showed that patients who received pomalidomide in a combination treatment after initial lenalidomide treatment achieved higher rates of very good partial response or better and longer progression-free survival than those who did not. The results of this analysis suggest that switching to a different class of drugs following the initial treatment may not be warranted after first relapse and pomalidomide-containing combination treatments are a more effective treatment following lenalidomide for patients with RRMM.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
开心寄松完成签到,获得积分10
1秒前
北宫完成签到 ,获得积分10
1秒前
wansida完成签到,获得积分10
5秒前
QXS完成签到 ,获得积分10
5秒前
6秒前
菠萝完成签到 ,获得积分10
6秒前
领导范儿应助Villanellel采纳,获得10
10秒前
wintersss完成签到,获得积分10
10秒前
尹尹发布了新的文献求助10
11秒前
量子星尘发布了新的文献求助10
13秒前
zzzzzz完成签到 ,获得积分10
17秒前
坦率的枕头完成签到,获得积分10
17秒前
XS_QI完成签到 ,获得积分10
17秒前
与共发布了新的文献求助10
20秒前
苑阿宇完成签到 ,获得积分10
20秒前
yck1027完成签到,获得积分10
21秒前
fatcat完成签到,获得积分10
21秒前
斯文败类应助Camus采纳,获得10
22秒前
24秒前
Tammy完成签到 ,获得积分10
24秒前
Herisland完成签到 ,获得积分10
26秒前
lulalula完成签到,获得积分10
27秒前
NEO完成签到 ,获得积分10
29秒前
zcydbttj2011完成签到 ,获得积分10
31秒前
温暖的小鸭子完成签到,获得积分10
33秒前
37秒前
王泽厚发布了新的文献求助20
38秒前
雪花发布了新的文献求助10
40秒前
周全完成签到 ,获得积分10
44秒前
water应助科研通管家采纳,获得10
45秒前
Owen应助科研通管家采纳,获得10
45秒前
内向忆南完成签到,获得积分10
48秒前
翱翔者完成签到 ,获得积分10
51秒前
kryptonite完成签到 ,获得积分10
51秒前
月军完成签到,获得积分10
52秒前
欢呼寻冬完成签到 ,获得积分10
53秒前
西安浴日光能赵炜完成签到,获得积分10
54秒前
Joy完成签到 ,获得积分10
55秒前
Olsters完成签到 ,获得积分10
58秒前
老程完成签到,获得积分10
59秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022